Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events.
The design and synthesis of new antithrombotic agents have led to numerous recent clinical trials to investigate their efficacy and safety. Analysis of the data from these trials, especially when the results were not totally expected, has provided interesting information, allowing a better understanding of the pathophysiology of thrombosis in various clinical situations. The aim of the present manuscript is to present the hypotheses on thrombogenesis generated by some of these recent clinical trials, notably those investigating the antithrombotic efficacy of a new synthetic and selective factor Xa inhibitor, fondaparinux. The antithrombotic efficacy of fondaparinux was recently investigated in a number of trials in the prevention and treatment of venous and arterial thrombotic disorders. In each case, the concept of the clinical efficacy of a selective factor Xa inhibitor has been proven. These trials have also clarified the implication and mode of action of factor Xa in these various types of thrombotic events. In the light of these trials, we discuss the clinical efficacy of such a selective factor Xa inhibitor, and other specific points such as the apparent lack of dose-dependency of its antithrombotic effect.
Drouet
L
L
Hôpital Lariboisière, Paris, France. ludovic.drouet@lrb.ap-hop-paris.fr
Bal Dit Sollier
C
C
D000925:Anticoagulants / Q000627:therapeutic use; D065427:Factor Xa Inhibitors; D000077425:Fondaparinux; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000502:physiology; D013923:Thromboembolism / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D020246:Venous Thrombosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D011134:Polysaccharides; D006493:Heparin; D013917:Thrombin; D000077425:Fondaparinux